Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?

Viking Therapeutics (VKTX) is set to report third-quarter earnings on Oct. 23, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 24 cents per share.Estimates for 2024 loss per share have risen slightly from 99 cents to $1.00 in the past 60 days. Over the same timeframe, loss per share estimates for 2025 have narrowed from $1.48 to $1.46. Image Source: Zacks Investment Research ...